HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Neutrogena Defending Class Action After Findings Of Benzene In SPF Products

Executive Summary

J&J unit faces allegations of having exposed Neutrogena sunscreen consumers to avoidably high levels of carcinogenic benzene in a case seeking class action status in California federal court.

You may also be interested in...



US Q1 Consumer Health Earnings Preview: Pivoting From Planning Changes To Parsing Results

Inflation's impact on consumer spending will be front and center in sector’s quarterly reports, beginning with J&J on 19 April. Potential impact also from price hikes common from most firms since early 2021 in response to increasing costs. Russia’s invasion of Ukraine also will prompt comment.

J&J Commits To Supply Chain Reforms In Benzene Class Action Settlement

Already in receipt of more than $9m in refund requests from purchasers of potentially benzene-contaminated Neutrogena and Aveeno sunscreen products following a July 2021 recall, J&J now is finalizing a US multidistrict class action settlement that will add to those costs and require steps to prevent further benzene issues.

‘Valisure Scenario’ Plan Should Be Ready In Consumer Health, Personal Care Firms’ Tool Kits

“What started a couple years ago with the discovery of nitrosamine in blood pressure and heart medicine has since evolved to benzene in hand sanitizer and sunscreen,” says Sedgwick International’s Amanda Combs about “Valisure scenario.”

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS151512

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel